目的探讨金匮肾气丸联合维生素D钙片治疗2型糖尿病性骨质疏松症(T2DOP)的临床疗效,以及对患者血清骨转换标志物、白细胞介素-1β(IL-1β)、基质金属蛋白酶-9(MMP-9)、超氧化物歧化酶(SOD)水平的影响。方法选择该院2021年1月至2022年10...目的探讨金匮肾气丸联合维生素D钙片治疗2型糖尿病性骨质疏松症(T2DOP)的临床疗效,以及对患者血清骨转换标志物、白细胞介素-1β(IL-1β)、基质金属蛋白酶-9(MMP-9)、超氧化物歧化酶(SOD)水平的影响。方法选择该院2021年1月至2022年10月收治的84例T2DOP患者作为研究对象,按随机数字表法将患者分为观察组(42例)和对照组(42例)。观察组采用金匮肾气丸联合维生素D钙片治疗,对照组单用维生素D钙片治疗,治疗24周后比较两组临床疗效。治疗前后检测两组患者第1~4腰椎(L 1~4)、股骨颈的骨密度(BMD),并对两组患者进行疼痛视觉模拟量表(VAS)评分。治疗前后检测两组患者的糖代谢指标[空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)]、血清骨转换标志物{25羟基维生素D[25(OH)D]、β-胶原特殊序列(β-Crosslaps)、总Ⅰ型胶原氨基端延长肽(Total-P1NP)、骨钙素N端中分子片段(N-MID)}以及IL-1β、MMP-9、SOD水平。统计两组不良反应发生情况。结果观察组总有效率为95.24%,明显高于对照组的76.19%(P<0.05)。治疗后,两组L 1~4 BMD以及血清25(OH)D、Total-P1NP、N-MID、SOD水平均高于治疗前(P<0.05),VAS评分、FPG、2 h PG、HbA1c以及血清β-Crosslaps、IL-1β、MMP-9水平均低于治疗前(P<0.05)。治疗后,观察组L 1~4 BMD以及血清25(OH)D、Total-P1NP、N-MID、SOD水平均高于对照组(P<0.05),VAS评分、FPG、2 h PG、HbA1c以及血清β-Crosslaps、IL-1β、MMP-9水平均低于对照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论金匮肾气丸联合维生素D钙片治疗T2DOP能有效调节患者血清骨转换标志物、IL-1β、MMP-9、SOD水平,改善糖代谢与骨代谢,提高临床疗效。展开更多
Background: Postpartum hemorrhage (PPH) is the major contributor to maternal mortality and morbidity worldwide as well as in Tanzania. Studies have shown Pre-eclampsia as a risk indicator for Postpartum hemorrhage and...Background: Postpartum hemorrhage (PPH) is the major contributor to maternal mortality and morbidity worldwide as well as in Tanzania. Studies have shown Pre-eclampsia as a risk indicator for Postpartum hemorrhage and D-dimer tends to rise in women with pre-eclampsia. Few studies that have shown the association between D-dimer and PPH have been controversial and differ according to ethnicity and lifestyle. Hence there is no suitable reference interval for D-dimer in predicting Postpartum hemorrhage among women with pre-eclampsia. Broad Objective: This study aimed to assess the association, sensitivity, and specificity of D-dimer as a laboratory predictor of postpartum hemorrhage among women with pre-eclampsia at KCMC hospital. Methodology: This was a hospital-based analytical cross-sectional study conducted at KCMC Hospital in Northern Tanzania from September 2022 to March 2023. A total of 195 women with pre-eclampsia were included in this study. Plasma D-dimer levels were taken from women with pre-eclampsia pre-delivery. Haematocrit was compared before and after delivery, and a fall of 10% was considered as Postpartum hemorrhage together with clinical assessment of the patient. Participants were divided among those who had severe features and those who did not have severe features and were further categorized into those who had PPH and those who did not have PPH. Logistic regression was used to determine the association between D-dimer and PPH adjusting for other factors. The Receiver Operating Curve (ROC) was used to evaluate the predictive value. Results: Higher median D-dimer levels were seen among women who had PPH compared to those who had no PPH. D-dimer was seen to be associated with PPH, thus for every unit increase of µg/ml of D-dimer among women who had pre-eclampsia without severe features there was a 14% significant increase in the odds of having postpartum hemorrhage and a 45% significant increase of having postpartum hemorrhage among those who had pre-eclampsia with severe features. Furthermore, the cut-off point of a D-dimer level of 0.66 µg/ml significantly predicts postpartum hemorrhage with a sensitivity of 75% and specificity of 55%. For those who had no severe features the cut-off point was 0.53 µg/ml with a sensitivity of 95% and specificity of 53%, and for those who had severe features the cut-off point was 3.58 µg/ml with a sensitivity of 50% and specificity of 96%. Conclusion: D-dimer can be used to predict postpartum hemorrhage among pre-eclampsia, especially among those who have severe features. This shows that D-dimer has specificity in predicting PPH in women with pre-eclampsia and can be applied in clinical services to save women from maternal morbidity and mortality. Blood products such as fresh frozen plasma, platelets, and whole blood together with tranexamic acid should be readily available in women with pre-eclampsia especially those with severe features with a D-dimer level of 3.58 µg/ml and above during delivery as they are at high risk of developing PPH.展开更多
文摘目的探讨金匮肾气丸联合维生素D钙片治疗2型糖尿病性骨质疏松症(T2DOP)的临床疗效,以及对患者血清骨转换标志物、白细胞介素-1β(IL-1β)、基质金属蛋白酶-9(MMP-9)、超氧化物歧化酶(SOD)水平的影响。方法选择该院2021年1月至2022年10月收治的84例T2DOP患者作为研究对象,按随机数字表法将患者分为观察组(42例)和对照组(42例)。观察组采用金匮肾气丸联合维生素D钙片治疗,对照组单用维生素D钙片治疗,治疗24周后比较两组临床疗效。治疗前后检测两组患者第1~4腰椎(L 1~4)、股骨颈的骨密度(BMD),并对两组患者进行疼痛视觉模拟量表(VAS)评分。治疗前后检测两组患者的糖代谢指标[空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)]、血清骨转换标志物{25羟基维生素D[25(OH)D]、β-胶原特殊序列(β-Crosslaps)、总Ⅰ型胶原氨基端延长肽(Total-P1NP)、骨钙素N端中分子片段(N-MID)}以及IL-1β、MMP-9、SOD水平。统计两组不良反应发生情况。结果观察组总有效率为95.24%,明显高于对照组的76.19%(P<0.05)。治疗后,两组L 1~4 BMD以及血清25(OH)D、Total-P1NP、N-MID、SOD水平均高于治疗前(P<0.05),VAS评分、FPG、2 h PG、HbA1c以及血清β-Crosslaps、IL-1β、MMP-9水平均低于治疗前(P<0.05)。治疗后,观察组L 1~4 BMD以及血清25(OH)D、Total-P1NP、N-MID、SOD水平均高于对照组(P<0.05),VAS评分、FPG、2 h PG、HbA1c以及血清β-Crosslaps、IL-1β、MMP-9水平均低于对照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论金匮肾气丸联合维生素D钙片治疗T2DOP能有效调节患者血清骨转换标志物、IL-1β、MMP-9、SOD水平,改善糖代谢与骨代谢,提高临床疗效。
文摘Background: Postpartum hemorrhage (PPH) is the major contributor to maternal mortality and morbidity worldwide as well as in Tanzania. Studies have shown Pre-eclampsia as a risk indicator for Postpartum hemorrhage and D-dimer tends to rise in women with pre-eclampsia. Few studies that have shown the association between D-dimer and PPH have been controversial and differ according to ethnicity and lifestyle. Hence there is no suitable reference interval for D-dimer in predicting Postpartum hemorrhage among women with pre-eclampsia. Broad Objective: This study aimed to assess the association, sensitivity, and specificity of D-dimer as a laboratory predictor of postpartum hemorrhage among women with pre-eclampsia at KCMC hospital. Methodology: This was a hospital-based analytical cross-sectional study conducted at KCMC Hospital in Northern Tanzania from September 2022 to March 2023. A total of 195 women with pre-eclampsia were included in this study. Plasma D-dimer levels were taken from women with pre-eclampsia pre-delivery. Haematocrit was compared before and after delivery, and a fall of 10% was considered as Postpartum hemorrhage together with clinical assessment of the patient. Participants were divided among those who had severe features and those who did not have severe features and were further categorized into those who had PPH and those who did not have PPH. Logistic regression was used to determine the association between D-dimer and PPH adjusting for other factors. The Receiver Operating Curve (ROC) was used to evaluate the predictive value. Results: Higher median D-dimer levels were seen among women who had PPH compared to those who had no PPH. D-dimer was seen to be associated with PPH, thus for every unit increase of µg/ml of D-dimer among women who had pre-eclampsia without severe features there was a 14% significant increase in the odds of having postpartum hemorrhage and a 45% significant increase of having postpartum hemorrhage among those who had pre-eclampsia with severe features. Furthermore, the cut-off point of a D-dimer level of 0.66 µg/ml significantly predicts postpartum hemorrhage with a sensitivity of 75% and specificity of 55%. For those who had no severe features the cut-off point was 0.53 µg/ml with a sensitivity of 95% and specificity of 53%, and for those who had severe features the cut-off point was 3.58 µg/ml with a sensitivity of 50% and specificity of 96%. Conclusion: D-dimer can be used to predict postpartum hemorrhage among pre-eclampsia, especially among those who have severe features. This shows that D-dimer has specificity in predicting PPH in women with pre-eclampsia and can be applied in clinical services to save women from maternal morbidity and mortality. Blood products such as fresh frozen plasma, platelets, and whole blood together with tranexamic acid should be readily available in women with pre-eclampsia especially those with severe features with a D-dimer level of 3.58 µg/ml and above during delivery as they are at high risk of developing PPH.
